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Sex steroid binding to human lymphocytes plasma
membrane
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Sex steroid hormones such as testosterone and
oestradiol induce immunomodulation of the
lymphoid system in vivo and in vitro, (Clemens et
al., 1979; Fuja Kotane, 1975; Kevorkov &
Shvetsov, 1979) and cytosolic binding has been
demonstrated in normal and pathological human
lymphocytes, (Danel et al., 1981). How the
hormones enter the cells is controversial: a
"passive" diffusion as described by Peck et al.
(1973) or a "facilitated" diffusion as postulated by
Milgrom et al. (1973).
Specific binding sites for steroid have been
demonstrated on the plasma membrane of target
cells (Nenci et al., 1980; Pietras & Szego, 1977,
1980) and steroid binding on their membrane
"receptors" induced cellular functions such as
cAMP uptake (Chew et al., 1974).
In the present study, human peripheral lympho-
cytes were characterized with regard to oestradiol
membrane binding sites. In order to eliminate
diffusion through the membrane and to study
external binding, steroid was covalently bound to
bovine serum albumin (BSA) to constitute a macro-
molecular complex which could not diffuse into the
cells and this complex was fluoresceinated.
Human peripheral blood from 30 healthy adult
donors and from 23 adult patients with chronic or
acute leukaemia from the Haematological Depart-
ment of the Institut J. Paoli-I. Calmettes (Marseille)
was collected in heparin. Peripheral blood mono-
nuclear cells (PBMC) were isolated by Ficoll-
Hypaque density gradient centrifugation, (Boyum,
1968). From healthy donors, lymphocyte sub-
populations were isolated by first removing
phagocytic cells with carbonyl iron and second by a
Ficoll-Hypaque gradient on rosetted (R) lympho-
cytes with sheep red blood cells (SRBC) (Fournier
& Bach, 1976). The two isolated cells sub-
populations R+ cells (T lymphocytes) and R-
cells (mostly B lymphocytes) were characterized by
SRBC rosettes, surface membrane immunoglobulin
(SIg) (Papamichail et al., 1971) and morphological
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identification by light microscopy after May
Grumwald Giemsa Staining.
These characterization techniques yielded the
following results: R- cells contained >90%
lymphocytes, <5% monocytes and <4% poly-
nuclear cells; 80-90% of these cells were SIg+ and
<5% re-rosetted with SRBC.
R+ cells contained >95% lymphocytes <2%
monocytes and <2% polynuclear cells. Less than
5% were SIg+ and >80% re-rosetted with SRBC.
R+ cells were tested after dissociation of rosettes
by ammonium chloride. Viability was >95% in
both groups.
R- cells were also tested after incubation with
ammonium chloride to eliminate its role in
oestradiol membrane binding.
In patient donors with acute leukaemia, poorly
differentiated lymphoma or chronic lymphocytic
leukaemia, the cells were isolated from peripheral
blood before chemotherapy and characterized by
the following tests: R and EAC rosette formation,
(Bianco et al., 1970), identification of rosetting cells
by spinning and staining with May Grumwald
Giemsa, cytotoxic assay with an anti-T lymphocyte
rabbit antiserum (Touraine et al., 1974) and deter-
mination of SIg.
For oestrogen binding assays we used oestradiol
covalently linked to BSA (steraloids). Each BSA
molecule carried on the average 22-25 oestradiol
molecules. 1, 3, 5 (10) Estratrien 3,17f# diol 6 one 6
CMO-BSA was fluoresceinated, (E2-BSA-FITC)
(Walter et al., 1978).
Cells (106) pre-incubated with latex particles in
1OOIul of Hank's medium, were incubated for
30min at 40C or 37°C with E2-BSA-FITC at
different concentrations, ranging from 0.1 to
4 x10- 5M for the conjugate. In some experiments
E2-BSA-FITC was incubated in the presence of
dihydrotestosterone (DHT) (10-5M) in the
medium. At the end of incubation tubes were
centrifuged 10min at 600g at 4°C and the pellet
was washed twice in Hanks solution. After the last
wash, the cells were placed on slides, dried in air,
fixed with 1% glutaraldehyde, or ethanol; the slides
were then mounted in glycerol and examined under
an Orthoplan Leitz microscope. The percentage of
fluorescent cells was obtained by counting 200 latex
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negative cells from each preparation. Controls were
incubated with BSA-FITC. Viability of cells was
checked at the end of each assay by trypan blue
exclusion and was invariably >90%. Each test was
run in triplicate and most experiments repeated at
least 5 times.
Carbonyl iron-treated peripheral blood mono-
nuclear cells (PBMC) from 30 normal male and
female subjects were incubated for 30min at 4°C or
37°C with E2-BSA-FITC at a concentration of
4 x 10-5M: the average percentage of fluorescent
cells was 5.2% (range 0-16%). Fluorescence was
bright and distributed over the cell surface. The
same test performed on the isolated R+ and R-
lymphocyte sub-populations gave significantly
different results. In 25 different R- cell
populations, the average percentage was 20%
(range 8-32), 18% (2-20) in males and 22% (9-32)
in females. In contrast, no binding occurred in R+
cell populations. The controls performed with BSA-
FITC alone were always negative. In the presence
of DHT, similar results were obtained thereby
ruling out the binding of E2-BSA-FITC to plasma
protein absorbed on the cell membrane. In order to
identify the E2-BSA-FITC fluorescent cell sub-
population, the same cells were incubated with E2-
BSA-FITC and rhodamine goat antibody (Fab'2)
to human Ig. (Biolyon). The incubation was
performed at 4°C for 30min to avoid capping of Ig.
Interestingly, the cells which were fluorescent for
FITC also fluoresced for rhodamine showing that
E2-BSA-FITC binding cells were B cells, but when
cells were first incubated at 37°C for 180min with
rhodamine Fab'2 antibodies to human Ig and
secondly with E2-BSA-FITC, we observed
rhodamine capping and diffusely distributed
fluorescein on the same cells (Figure 1) E2-BSA-
FITC did not interfere with Ig capping
mechanisms.
E2-BSA-FITC binding was tested in 23 mono-
clonal cell populations of chronic and acute
lymphocyte leukaemia (Table I). No binding was
observed in T or "null" leukaemia. Significant
binding occurred only in some B proliferations. In
two cases of B acute lymphocytic leukaemia, 70%
and 100% of the cells bound E2-BSA-FITC.
Consequently normal R- cells or leukaemia B cells
were used to characterize the steroid binding. The
percentage of E2-BSA-FITC binding cells from the
same donor did not change when blood was
collected at different times. Furthermore, the
freezing time which ranged from one month to one
year did not affect binding since it varied only from
27-34% in a 15 test control experiment.
Saturation binding curve Cells (106) were incubated
with increasing concentrations of E2-BSA-FITC
from 0.1 to 4 x 10 5M. Typical results are shown
in Figure 2 where the percentage of fluorescent cells
was enhanced from 6% at 0.1 x 10-5M to 20% at
Figure 1 Rhodamine-FITC membrane staining on the same cell. Photo-micrography of human lymphocytes
showing rhodamine fluorescence in a cap and diffuse plasma membrane FITC fluorescence. This double
staining was obtained by a double incubation as follows. First R-lymphocytes were incubated with
rhodamine-conjugated fragments (Fab'2) antibodies to human Ig for 180min at 37°C to obtain a rhodamine
cap and second, with E2-BSA-FITC 10-5M for 30min at 37°C. After two washes viability was checked by
trypan blue exclusion and exceeded 90%. The cells were examined with an Orthoplan Leitz microscope using
Block 12 (Leitz) for FITC and Block N2 for rhodamine. The photography was obtained by a superimpression
of the both photographs of the same cells.SEX STEROID BINDING TO HUMAN LYMPHOCYTES
Table I Sex steroid binding to pathological cell populations
Immunological characterization From total cellpopulation
Patients % of % E2-BSAfluorescent
Disease Identification Sex Age pathol. cells Lymphocyte subset cells
RIC M 60 60 B(y K) 9
EYM F 50 100 B(/c K) 74
CUC M 60 75 B (U6K) 3
HOL M 65 100 B(PK) 27
JAU M 42 100 B(P K) 29
CLL LIM F 50 100 B(P K) 32
ZER F 65 60 B(K) 0
DER F 70 80 BI( K) 11
DIL M 50 100 B (aA) 36
BER M 60 50 B(y K) 32
PAC F 50 80 B(y K) 11
DEH F 27 100 T 0
BES M 34 100 T 0
LAL F 17 86 Not T nor B 2
BRE M 16 100 Not T nor B 3
ALL CAR F 72 67 Not T nor B 5
DEB M 64 100 Not T nor B 0
HAN M 17 96 Not T nor B 0
HEL M 14 70 Not T nor B 0
LOU F 16 90 Not T nor B 0
PDL LAT M 15 80 B(P K) 4
EST M 48 95 B(py K) 9
Peripheral blood cells from patients with CLL (chronic lymphocytic leukaemia), ALL (acute lymphocytic
leukaemia) or PDL (poorly differentiated lymphoma) were isolated as described in the text.
They were tested by usual immunological methods and identified as:
- B lymphocytes by determination of SIg,
- T lymphocytes by R rosette and/or using an heterologous rabbit antiserum,
- neither T nor B lymphocytes when these tests were negative.
1xl10-5M, and remained stable until 4x 10-5M.
Similar binding curves were obtained with several
cell populations.
Determination of binding dissociation Cell
preparations were first incubated with a saturation
concentration of E2-BSA-FITC (4x 10-5M) for
30min at 37°C. At the end of incubation, the
number of fluorescent cells was counted and
regarded as equivalent to 100%. After two washes
the second step was performed by incubating these
cell preparations with non-fluorescent E2-BSA at
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E2-BSA-FITC concentration 1.5 x 10-4M) for 30min at 37°C. A decrease in the
percentage of fluorescent cells was obtained as a aturation binding curve. Percent of function of the concentration of non-fluorescent E2-
ll1s obtained when 106 human normal R- BSA added (Figure 3).
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Specificity of E2-BSA-FITC binding Coincubation
of E2-BSA-FITC at saturation concentration with
non-fluorescent competitors at a 100-fold excess
concentration was not possible because these
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incubated in Hanks medium with E2-BSA-FITC at
concentrations ranging from 0.1 to 4 x 10-5M for
30min at 37°C. Each E2-BSA-FITC concentration was
run in triplicate, the mean values of which are
represented by the points shown.
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Figure 3 Dissociation binding curve. Percentage of
fluorescent cells obtained after two incubations: First:
R-lymphocytes suspended in Hanks medium were
incubated with E2-BSA-FITC at 10-5M (saturation
concentration) for 30min at 37°C and washed twice.
The percentage of fluorescent cells determined used as
100%. Second: After the two washes, the cells were
incubated with non-fluorescent E2-BSA at different
final concentrations from 4xl-6M to 1.5x 10-4M.
Each incubation was performed for 30min at 37°C. At
the end of each experiment the percentage of
fluorescent cells was determined. Controls: the cells
were exposed to Hanks medium alone, during the
second incubation. Each point represents mean of
triplicate determinations.
complexes dissolved poorly in our buffer at these
concentrations. Therefore cells were incubated for
30min at 37°C with non-fluorescent competitors
steroid-BSA (1.5 x 10-4M), then E2-BSA-FITC was
added (1 x 10-5M) and the incubation was
continued for a further 30min at 37°C. The
percentage of fluorescent cells from this double
incubation was compared with that obtained after a
single incubation with E2-BSA-FITC. The non-
fluorescent steroid-BSA conjugates used were: 1,3,5,
(10) Estratrien 3,17# diol 6 CMO-BSA (E2-BSA)
- 1,3,5, (10) Estratrien 3 ol-6,17 dione 6-CMO-BSA
(E1-BSA)-4 androsten 17fl ol 3 one 3 CMO-BSA
(Testo-BSA)-4 androsten 3,17 dione, 3 CMO-BSA-4
pregnen 3,20 dione 3 CMO-BSA. These molecules
are the same as E2-BSA except in C 17 or C 3 and
on A cycle.
Under our experimental conditions, 90% of E2-
BSA-FITC binding was inhibited (77-100) by E2-
BSA. 50% (45-55) by E2-BSA and less than 20%
(0-20) by Testo-BSA and 4 androsten 3,17 dione-
BSA as well as pregnen 3,20 Dione-BSA. BSA did
not prevent E2-BSA-FITC binding.
Time temperature and pH dependence of
binding As shown in Figure 4 E2-BSA-FITC
binding was maximum after 10min of incubation at
37°C and was stable up to 360min. When the
steroid was used up to and at saturation concen-
tration (10-M) similar binding kinetics and levels
were obtained at 4°C and 37°C. However when the
concentration of E2-BSA-FITC used was less than
saturation concentration, the binding kinetic was
temperature dependent as indicated in Figure 4.
The maximum binding was the same at both
temperatures but delayed at 4°C. The pattern of
immunofluorescence over the cell membrane was
studied at 4°C and 37°C. A temperature-dependent
phenomenon of capping is known to occur with
multivalent ligands bound to plasma membrane of
freely suspended cells. This process did not occur
with the binding of E2-BSA-FITC to the plasma
membrane of lymphocytes.
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Figure 4 Time temperature dependence of binding.
Percentage of fluorescent cells obtained after
incubation of CLL cells with E2-BSA-FITC from 10 to
300min at 4°C or 37°C. E2-BSA-FITC was used at
saturation concentration (10-5M) at 4°C and at 37°C
and at a concentration of 5 xl0-7M at 4°C and at
37°C. Each point represents mean of triplicate
determinations.
Changing the buffer pH from 6.2 to 8.2 which is
within the range of cell viability did not noticeably
affect binding.
Effect of enzyme digestion A preliminary attempt
to characterize the E2-BSA-FITC binding sites on
lymphocytes, was performed by exposing the cells
to enzymes that commonly modify cell membrane
receptors: SIg+ lymphocytes were incubated 30min
at 37°C in Hank's medium with trypsin (0.25%) or
neuraminidase (10jIgml-). The variability checked
after each incubation was always >90%. Binding
with E2-BSA-FITC was checked as previously
stated: neuraminidase had no effect whereas trypsin
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inhibited 100% of E2-BSA-FITC binding. Recovery
of sex steroid binding after exposure to trypsin, was
tested by incubating cells in the presence or absence
of cycloheximide (50 gml-1) (inhibitor of protein
synthesis) in culture medium (RPMI+20% foetal
calf serum) at 37°C in CO2 atmosphere. After 3h,
cells incubated alone recovered 20% of their initial
E2-BSA-FITC binding and 100% after 18h. Cells
incubated in the presence of cycloheximide
recovered <10% of their binding after 18h
although cell viability was >80%.
Our experiments show that sex steroid macro-
molecular complex constituted by oestradiol
covalently linked to bovine serum albumin binds to
the plasma membrane of a sub-population of
human B lymphocytes regardless of the sex of the
donor. Similar binding occurred on some B acute
and chronic leukaemia cells. The macromolecular
complex E2-BSA did not bind to T cells; BSA by
itself bound to neither B nor T cells. Given the
limits of our fluorescent technique, accurate
characterization of the binding is impossible.
However, we can draw some conclusions: the
binding occurred at the plasma membrane of the
cells and was saturable, rapid, reversible, partly
temperature dependent and steric specific.
Moreover, it was insensitive to sialic acid digestion
with neuraminidase but was markedly reduced by
proteolysis with trypsin. This effect was reversed by
an 18h incubation in serum containing culture
medium but not when an inhibitor of protein
synthesis was added.
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